Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by Advanced Magnetic Research Institute International.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Advanced Magnetic Research Institute International
ClinicalTrials.gov Identifier:
NCT00134524
First received: August 22, 2005
Last updated: July 8, 2007
Last verified: July 2007

August 22, 2005
July 8, 2007
July 2005
Not Provided
  • Improvement in neurologic function following procedure
  • Improvement in DPN related pain following procedure
  • Subject tolerance to the MME procedure
  • Improvement in neurologic function following procedure.
  • Improvement in DPN related pain following procedure.
  • Subject tolerance to the MME procedure
Complete list of historical versions of study NCT00134524 on ClinicalTrials.gov Archive Site
  • Neurologic function at 6 month follow-up
  • Pain level at 6 month follow-up
  • Quality of Life assessments at baseline, post-procedure and 6 month follow-up
  • Neurologic function at 6 month follow-up.
  • Pain level at 6 month follow-up.
  • Quality of Life assessments at baseline, post-procedure and 6 month follow-up.
Not Provided
Not Provided
 
The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy
A Randomized, Sham-Controlled Clinical Study to Evaluate The Effect of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy

This study is intended to demonstrate that exposure to a high intensity, DC electromagnetic field, as supplied by the investigational device known as the Molecular Magnetic Energizer (MME), will create a clinically meaningful improvement in pain and nerve dysfunction in the feet of patients with diabetic peripheral neuropathy (DPN).

Diabetic peripheral neuropathy (DPN) affects up to 1/2 of diabetics, both type I and II. It contributes to limb amputation, and can cause painful symptoms which are difficult to treat. Application of a high intensity, DC electromagnetic field, as supplied by the investigational device the Magnetic Molecular Energizer (MME) has shown in a pilot study with participants having DPN in their feet, to have created significant improvement in painful symptoms and improved measures of neurologic function in 7 of 10 participants. This study will enroll participants and evaluate them at baseline with regard to pain levels, nerve function and quality of life. They will then be randomized to receive 120 hr exposure to either active MME procedure, or sham procedure. Following the 120 hrs the participants will then receive the same evaluation for pain level, nerve function and quality of life. These evaluations will be repeated a final time 6 months following. The participants will be blinded to whether they receive the active or sham procedure.

The MME procedure consists of laying on a bed with the feet lying in the space between two large electromagnetic coils which, when activated, produce a DC magnetic field measuring 5000 gauss. The participants will lay on the bed with feet in the magnetic field for 8 to 12 hours a day for 10 to 16 days in succession. Breaks are allowed, and no restraints are required. The procedure may be done at night so that participants may sleep.

Pain assessment will be done by self assessment using rating with the Visual Analogue Scale.

Neurologic function will be assessed with Cutaneous Perception Threshold testing using the Neurometer, a commercially available, FDA approved device.

Quality of life assessment will be by the Neuropathy Specific Quality of Life Questionnaire.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Diabetic Neuropathies
  • Pain
  • Neuralgia
Procedure: MME procedure
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
100
January 2008
Not Provided

Inclusion Criteria:

  • Subjects with diabetic peripheral neuropathy in feet with associated pain/discomfort.
  • Stable and controlled diabetes with hemoglobin A1c level less than 9.0% at entry into the study. Diabetes type I or type II accepted.
  • Subjects must be able to read English.

Exclusion Criteria:

  • Pacemakers, defibrillators, aneurysm clips, cochlear implants, any metallic particles in eyes or ferromagnetic metal shrapnel, projectile or implant in body.
  • Pregnant women
  • Concurrent neuropathy not due to diabetes.
  • Unstable cardiac disease or uncontrolled blood pressure.
  • Renal failure
  • Active hepatitis
  • History of nerve injury to lower extremities.
  • History of spinal surgery or total knee arthroplasty
  • Current malignancy
  • Alcoholism
  • History of stroke
  • Seizure disorder
  • Current use of long acting narcotic medication
  • Skin ulceration or breakdown of the lower extremities
  • Peripheral vascular disease sufficient to cause extremity pain at rest.
Both
18 Years to 79 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00134524
AMRI-DPN-01
No
Not Provided
Advanced Magnetic Research Institute International
Not Provided
Study Director: Wayne R Bonlie, MD AMRI International
Advanced Magnetic Research Institute International
July 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP